<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1439</article-id><article-id pub-id-type="doi">10.36691/RJA1439</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Patient with polymorbid pathology. Possibilities of therapy with monoclonal antibodies</article-title><trans-title-group xml:lang="ru"><trans-title>Больной с полиморбидной патологией. Возможности терапии моноклональными антителами</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7691-4584</contrib-id><contrib-id contrib-id-type="scopus">6506637441</contrib-id><contrib-id contrib-id-type="researcherid">AAI-3342-2020</contrib-id><contrib-id contrib-id-type="spin">9941-7013</contrib-id><name-alternatives><name xml:lang="en"><surname>Astafyeva</surname><given-names>Natalia G.</given-names></name><name xml:lang="ru"><surname>Астафьева</surname><given-names>Наталья Григорьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Doctor of Medical Sciences, professor</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, зав.кафедрой клинической иммунологии и аллергологии</p></bio><email>astang@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8108-782X</contrib-id><contrib-id contrib-id-type="spin">3026-5331</contrib-id><name-alternatives><name xml:lang="en"><surname>Udovichenko</surname><given-names>Ekaterina N.</given-names></name><name xml:lang="ru"><surname>Удовиченко</surname><given-names>Екатерина Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Assistant Professor</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, доцент</p></bio><email>udokate@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Saratov State Medical University n.a. V.I. Razumovskiy” of the Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО Саратовский государственный медицинский университет имени В.И. Разумовского МЗ РФ</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2021-06-03" publication-format="electronic"><day>03</day><month>06</month><year>2021</year></pub-date><pub-date date-type="pub" iso-8601-date="2021-06-26" publication-format="electronic"><day>26</day><month>06</month><year>2021</year></pub-date><volume>18</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>123</fpage><lpage>130</lpage><history><date date-type="received" iso-8601-date="2021-04-04"><day>04</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-05-29"><day>29</day><month>05</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Фармарус Принт Медиа</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2023-07-06"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/1439">https://rusalljournal.ru/raj/article/view/1439</self-uri><abstract xml:lang="en"><p>With the widespread increase in the number of patients with allergic pathology, doctors in clinical practice increasingly have to observe the simultaneous development of several nosological forms in the same patient. Frequent occurrence of a combination of lesions of the skin and respiratory tract in patients with atopy (atopic dermatitis, allergic rhinitis, and atopic bronchial asthma) is traditionally considered within the framework of comorbidity and suggests a number of therapeutic interventions given the similarity of the pathogenesis. However, phenotypic or endotypic differences exist between patients (e.g., triggers, age, persistence of manifestations, degree and type of inflammation, severity of symptoms, and response to treatment), for which it is more correct to use the term multimorbidity. The strategy of precision medicine for patients with several immune-mediated diseases should focus on identifying not only the general features of the disease, but also the pathogenetic mechanisms in the target organs. Because of these differences, the sensitivity to therapeutic interventions by target organs can vary. Herein, a clinical case of a patient with comorbid pathology ― chronic spontaneous urticaria, allergic rhinitis, and bronchial asthma ―was analyzed. Respiratory manifestations (rhinitis and asthma) were mild to severe. Chronic urticaria had the most severe disease course and resistant to antihistamines, which are considered first and second lines of drugs according to federal and international clinical guidelines that required the use of monoclonal antibodies. Anti-IgE therapy with omalizumab had a rapid and complete effect on urticaria symptoms, but respiratory symptoms were less responsive to treatment. In patients with multimorbid pathology, therapy should be individualized in terms of targeted drugs and their dosage.</p></abstract><trans-abstract xml:lang="ru"><p>На фоне роста случаев аллергии врачам в клинической практике приходится наблюдать одновременное развитие нескольких нозологических форм у одного и того же пациента. Частое сочетание поражения кожи и респираторного тракта при атопии традиционно рассматривается в рамках коморбидности и предполагает ряд терапевтических вмешательств с учётом сходного патогенеза процессов. Однако существуют фено-/эндотипические различия между пациентами (в триггерах, возрасте, стойкости проявлений, степени и виде воспаления, тяжести симптомов и реакции на лечение), которые более корректно обозначать термином мультиморбидность. Стратегия прецизионной медицины для мультиморбидных пациентов должна быть ориентирована на выявление не только общих черт заболевания, но и индивидуальных механизмов воспаления в таргетных органах. В силу этого чувствительность к терапевтическим вмешательствам со стороны органов-мишеней может быть различной.</p> <p>Проанализирован клинический случай больной с сочетанной патологией ― хронической спонтанной крапивницей, аллергическим ринитом и бронхиальной астмой, при этом только для хронической спонтанной крапивницы отмечено наиболее тяжёлое течение вследствие её резистентности к антигистаминным препаратам, что потребовало применения моноклональных антител. Анти-IgE-терапия омализумабом оказала быстрый и полный эффект в отношении симптомов крапивницы, но респираторные симптомы были менее чувствительны к проводимому лечению.</p> <p>При назначении терапии пациентам с мультиморбидной патологией необходимы персонифицированный выбор таргетных препаратов и их дозирование.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic spontaneous urticarial</kwd><kwd>bronchial asthma</kwd><kwd>pollen allergic rhinitis</kwd><kwd>multimorbidity</kwd><kwd>anti-IgE therapy</kwd><kwd>monoclonal antibodies</kwd><kwd>omalizumab</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая спонтанная крапивница</kwd><kwd>бронхиальная астма</kwd><kwd>пыльцевой аллергический ринит</kwd><kwd>мультиморбидность</kwd><kwd>анти-IgE-терапия</kwd><kwd>моноклональные антитела</kwd><kwd>омализумаб</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Pawankar R, Canonica GW, Holgate ST, Lockey RF, editors. WAO White Book on Allergy. Copyright 2011 World Allergy Organization. Available from: https://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf</mixed-citation><mixed-citation xml:lang="ru">Pawankar R., Canonica G.W., Holgate S.T., Lockey R.F., editors. WAO White Book on Allergy. Copyright 2011 World Allergy Organization. Available from: https://www.worldallergy.org/UserFiles/file/WAO-White-Book-on-Allergy_web.pdf</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Shirinsky VS, Shirinsky IV. Comorbid diseases-an actual problem of clinical medicine. Siberian Medical Journal. 2014;29(1):7–12. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Ширинский В.С., Ширинский И.В. Коморбидные заболевания ― актуальная проблема клинической медицины // Сибирский медицинский журнал. 2014. Т. 29, № 1. C. 7–12.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Lazebnik LB. Aging and polymorbidity. Consilium medicum. 2005;7(12):993–996. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Лазебник Л.Б. Старение и полиморбидность // Consilium medicum. 2005. Т. 7, № 12. С. 993–996.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23(7):455–468. doi: 10.1016/0021-9681(70)90054-8</mixed-citation><mixed-citation xml:lang="ru">Feinstein A.R. The pre-therapeutic classification of co-morbidity in chronic disease // J Chronic Dis. 1970. Vol. 23, N 7. Р. 455–468. doi: 10.1016/0021-9681(70)90054-8</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Wedback ЕH, Eriksson NE, Movérare R, Malcus I. Seasonal non-allergic rhinitis (SNAR) – a new disease entity? A clinical and immunological comparison between SNAR, seasonal allergic rhinitis and persistent non-allergic rhinitis. Rhinology. 2005;43(2):86–92.</mixed-citation><mixed-citation xml:lang="ru">Wedback E.H., Eriksson N.E., Movérare R., Malcus I. Seasonal non-allergic rhinitis (SNAR) – a new disease entity? A clinical and immunological comparison between SNAR, seasonal allergic rhinitis and persistent non-allergic rhinitis // Rhinology. 2005. Vol. 43, N 2. Р. 86–92.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72(9):1297–1305. doi: 10.1111/all.13162</mixed-citation><mixed-citation xml:lang="ru">Hellings P.W., Fokkens W.J., Bachert C., et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement // Allergy. 2017. Vol. 72, N 9. Р. 1297–1305. doi: 10.1111/all.13162</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70(11):1372–1392. doi: 10.1111/all.12686</mixed-citation><mixed-citation xml:lang="ru">Bousquet J., Schunemann H.J., Fonseca J., et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation // Allergy. 2015. Vol. 70, N 11. Р. 1372–1392. doi: 10.1111/all.12686</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Vadasz Z, Kessel A, Hershko AY, et al. Seasonal exacerbation of asthma is frequently associated with recurrent episodes of acute urticaria. Int Arch Allergy Immunol. 2016;169(4):263–266. doi: 10.1159/000446183</mixed-citation><mixed-citation xml:lang="ru">Vadasz Z., Kessel A., Hershko A.Y., et al. Seasonal exacerbation of asthma is frequently associated with recurrent episodes of acute urticaria // Int Arch Allergy Immunol. 2016. Vol. 169, N 4. Р. 263–266. doi: 10.1159/000446183</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Asero R, Madonini E. Bronchial hyperresponsiveness is a common feature in patients with chronic urticaria. J Investig Allergol Clin Immunol. 2006;16(1):19–23.</mixed-citation><mixed-citation xml:lang="ru">Asero R., Madonini E. Bronchial hyperresponsiveness is a common feature in patients with chronic urticaria // J Investig Allergol Clin Immunol. 2006. Vol. 16, N 1. Р. 19–23.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Isik AR, Karakaya G, Celikel S, et al. Association between asthma, rhinitis, and NSAID hypersensitivity in chronic urticaria patients and prevalence rates. Int Arch Allergy Immunol. 2009;150(3):299–306. doi: 10.1159/000222683</mixed-citation><mixed-citation xml:lang="ru">Isik A.R., Karakaya G., Celikel S., et al. Association between asthma, rhinitis, and NSAID hypersensitivity in chronic urticaria patients and prevalence rates // Int Arch Allergy Immunol. 2009. Vol. 150, N 3. Р. 299–306. doi: 10.1159/000222683</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice. Drug Des Devel Ther. 2019;6:3181–3186. doi: 10.2147/DDDT.S214307</mixed-citation><mixed-citation xml:lang="ru">Vollono L., Piccolo A., Lanna C., et al. Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice // Drug Des Devel Ther. 2019. N 13. Р. 3181–3186. doi: 10.2147/DDDT.S214307</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Greaves M, Sabroe R. PL007 Urticaria and autoimmunity. Journal of the European Academy of Dermatology and Venereology. 1997;9:S2. doi:10.1016/s0926-9959(97)88838-1</mixed-citation><mixed-citation xml:lang="ru">Greaves M., Sabroe R. PL007 Urticaria and autoimmunity // Journal of the European Academy of Dermatology and Venereology. 1997. Vol. 9. S2. doi: 10.1016/s0926-9959(97)88838-1</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with metaanalysis. Allergy. 2020;75(2):423–432. doi: 10.1111/all.14037</mixed-citation><mixed-citation xml:lang="ru">Fricke J., Ávila G., Keller T., et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with metaanalysis // Allergy. 2020. Vol. 75, N 2. Р. 423–432. doi: 10.1111/all.14037</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Kozel MA, Sabroe R. Chronic urticaria: aetiology, management and current and future treatment options. Drugs. 2004;64(22): 2515–2536. doi: 10.2165/00003495-200464220-00003</mixed-citation><mixed-citation xml:lang="ru">Kozel M.A., Sabroe R. Chronic urticaria: aetiology, management and current and future treatment options // Drugs. 2004. Vol. 64, N 22. Р. 2515–2536. doi: 10.2165/00003495-200464220-00003</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–887. doi: 10.1111/all.12313</mixed-citation><mixed-citation xml:lang="ru">Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update // Allergy. 2014. Vol. 69, N 7. Р. 868–887. doi: 10.1111/all.12313</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Konstantinou GN, Asero R, Ferrer M, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy. 2012;68(1):27–36. doi: 10.1111/all.12056</mixed-citation><mixed-citation xml:lang="ru">Konstantinou G.N., Asero R., Ferrer M., et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria // Allergy. 2012. Vol. 68, N 1. Р. 27–36. doi: 10.1111/all.12056</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy. 2017;72(10):1440–1460. doi: 10.1111/all.13182</mixed-citation><mixed-citation xml:lang="ru">Kolkhir P., Metz M., Altrichter S., Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review // Allergy. 2017. Vol. 72, N 10. Р. 1440–1460. doi: 10.1111/all.13182</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Kolkhir P, Church M, Weller K, et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. Allergy Clin Immunol. 2017;139(6):1772–1781.e1. doi: 10.1016/j.jaci.2016.08.050</mixed-citation><mixed-citation xml:lang="ru">Kolkhir P., Church M., Weller K., et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know // Allergy Clin Immunol. 2017. Vol. 139, N 6. Р. 1772–1781.e1. doi: 10.1016/j.jaci.2016.08.050</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39(6):777–787. doi: 10.1111/j.1365-2222.2009.03256.x</mixed-citation><mixed-citation xml:lang="ru">Kaplan A.P., Greaves M. Pathogenesis of chronic urticaria // Clin Exp Allergy. 2009. Vol. 39, N 6. Р. 777–787. doi: 10.1111/j.1365-2222.2009.03256.x</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Altrichter S, Peter H, Pisarevskaja D, et al. IgE mediated autoallergy against thyroid peroxidase – a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6(4):e14794. doi: 10.1371/journal.pone.0014794</mixed-citation><mixed-citation xml:lang="ru">Altrichter S., Peter H., Pisarevskaja D., et al. IgE mediated autoallergy against thyroid peroxidase ― a novel pathomechanism of chronic spontaneous urticaria? // PLoS One. 2011. Vol. 6, N 4. Р. e14794. doi: 10.1371/journal.pone.0014794</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Staubach P, Vonend A, Burow G, et al. Patients with chronic urticaria exhibit increased rates of sensitisation to Candida albicans, but not to common moulds. Mycoses. 2009;52(4):334–338. doi: 10.1111/j.1439-0507.2008.01601.x</mixed-citation><mixed-citation xml:lang="ru">Staubach P., Vonend A., Burow G., et al. Patients with chronic urticaria exhibit increased rates of sensitisation to Candida albicans, but not to common moulds // Mycoses. 2009. Vol. 52, N 4. Р. 334–338. doi: 10.1111/j.1439-0507.2008.01601.x</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12(4):406–411. doi: 10.1097/aci.0b013e328355365a</mixed-citation><mixed-citation xml:lang="ru">Metz M., Maurer M. Omalizumab in chronic urticaria // Curr Opin Allergy Clin Immunol. 2012. Vol. 12, N 4. Р. 406–411. doi: 10.1097/aci.0b013e328355365a</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria. JAMA Dermatology. 2019;1(155):29–38. doi: 10.1001/jamadermatol.2018.3447</mixed-citation><mixed-citation xml:lang="ru">Tharp M.D., Bernstein J.A., Kavati A., et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria // JAMA Dermatology. 2019. Vol. 1, N 155. Р. 29–38. doi: 10.1001/jamadermatol.2018.3447</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi: 10.1111/all.13397</mixed-citation><mixed-citation xml:lang="ru">Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria // Allergy. 2018. Vol. 73, N 7. Р. 1393–1414. doi: 10.1111/all.13397</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Federal clinical guidelines of the Federal State Budgetary Institution GNCDC. (In Russ). Available from: http://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2017</mixed-citation><mixed-citation xml:lang="ru">Федеральные клинические рекомендации ФГБУ ГНЦДК. 2017. Режим доступа: http://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2017. Ссылка активна на 03.02.2021.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139(3):1059–1061. doi: 10.1016/j.jaci.2016.07.047</mixed-citation><mixed-citation xml:lang="ru">Gericke J., Metz M., Ohanyan T., et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria // J Allergy Clin Immunol. 2017. Vol. 139, N 3. Р. 1059–1061. doi: 10.1016/j.jaci.2016.07.047</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Arnau AM, Santiago VA, Tomás BJ, et al. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria. J Investig Allergol Clin Immunol. 2019;29(5):338–348. doi: 10.18176/jiaci.0323</mixed-citation><mixed-citation xml:lang="ru">Arnau A.M., Santiago V.A., Tomás B.J., et al. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria // J Investig Allergol Clin Immunol. 2019. Vol. 29, N 5. Р. 338–348. doi: 10.18176/jiaci.0323</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Vadasz Z, Tal Y, Rotem M, et al. Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients. J Allergy Clin Immunol Pract. 2017;5(6):1743–1745. doi: 10.1016/j.jaip.2017.08.035</mixed-citation><mixed-citation xml:lang="ru">Vadasz Z., Tal Y., Rotem M., et al. Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients // J Allergy Clin Immunol Pract. 2017. Vol. 5, N 6. Р. 1743–1745. doi: 10.1016/j.jaip.2017.08.035</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Ren Z, Wedner HJ. Long term efficacy of Omalizumab for patients with refractory chronic urticaria and angioedema. Journal of Allergy and Clinical Immunology. 2018;141(2):AB52. doi: 10.1016/j.jaci.2017.12.167</mixed-citation><mixed-citation xml:lang="ru">Ren Z., Wedner H.J. Long term efficacy of Omalizumab for patients with refractory chronic urticaria and angioedema // Journal of Allergy and Clinical Immunology. 2018. Vol. 141, N 2. Р. AB52. doi: 10.1016/j.jaci.2017.12.167</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Asero R, Canonica GW, Cristaudo A, et al. Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: an Italian perspective. Curr Opin Allergy Clin Immunol. 2017;17(6):453–459. doi: 10.1097/aci.0000000000000404.</mixed-citation><mixed-citation xml:lang="ru">Asero R., Canonica G.W., Cristaudo A., et al. Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: an Italian perspective // Curr Opin Allergy Clin Immunol. 2017. Vol. 17, N 6. Р. 453–459. doi:10.1097/aci.0000000000000404.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
